Stay updated on Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.
    Difference
    0.8%
    Check dated 2025-06-19T19:11:00.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated to announce a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.2.
    Difference
    1%
    Check dated 2025-06-05T07:36:09.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    The page has removed the phrase 'Last Update Posted (Estimated)' and replaced it with 'Last Update Posted'.
    Difference
    0.0%
    Check dated 2025-05-14T20:00:18.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page has updated its date information, with new dates added for May 2025 and March 2026, while several previous dates have been removed.
    Difference
    0.7%
    Check dated 2025-05-07T18:55:06.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:40:25.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the removal of detailed study objectives and treatment protocols for a clinical trial on Hodgkin lymphoma, while adding new identifiers and collaborators related to the study.
    Difference
    51%
    Check dated 2025-04-16T01:12:12.000Z thumbnail image

Stay in the know with updates to Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.